Published in Prog Clin Biol Res on January 01, 1983
Characterization of the products of DNA-directed DNA polymerases in oncogenic RNA viruses. Nature (1970) 5.23
DNA-directed DNA polymerase activity in oncogenic RNA viruses. Nature (1970) 4.81
Synthetic DNA-RNA hybrids and RNA-RNA duplexes as templates for the polymerases of the oncogenic RNA viruses. Nature (1970) 3.98
Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma (1984) 3.74
Simultaneous detection of reverse transcriptase and high molecular weight RNA unique to oncogenic RNA viruses. Science (1971) 3.68
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res (1992) 2.83
Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst (1995) 2.47
Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. Cancer Res (1983) 2.46
A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res (1999) 2.33
Presence in human breast cancer of RNA homologous to mouse mammary tumour virus RNA. Nature (1972) 2.31
Mechanisms of receptor-mediated rhinovirus neutralization defined by two soluble forms of ICAM-1. J Virol (1991) 2.30
Major pol gene progenitors in the evolution of oncoviruses. Science (1984) 2.28
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 2.28
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res (2001) 2.01
A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci U S A (1981) 2.00
In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst (1997) 1.92
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology (1999) 1.92
A new class of endogenous human retroviral genomes. Science (1985) 1.89
Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res (1986) 1.86
Generation of human monoclonal antibodies reactive with human mammary carcinoma cells. Proc Natl Acad Sci U S A (1980) 1.86
Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst (2000) 1.85
Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res (1986) 1.84
Evidence for translation of viral-specific RNA in cells of a mouse mammary carcinoma. Proc Natl Acad Sci U S A (1972) 1.76
Detection and cloning of human DNA sequences related to the mouse mammary tumor virus genome. Proc Natl Acad Sci U S A (1982) 1.74
Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res (2000) 1.71
DNA polymerase activities in varions of visna virus, a causative agent of a "slow" neurological disease. Proc Natl Acad Sci U S A (1971) 1.67
Identification of the coding region for a second Epstein-Barr virus nuclear antigen (EBNA 2) by transfection of cloned DNA fragments. EMBO J (1985) 1.65
RNA-dependent DNA polymerase activity in virus-like particles isolated from human milk. Nature (1971) 1.63
Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases. Nature (1984) 1.62
In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst (1990) 1.61
Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res (1991) 1.60
99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma. J Nucl Med (2001) 1.59
Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst (1992) 1.59
DNA polymerase activities and nucleic acid components of virions isolated from a spontaneous mammary carcinoma from a rhesus monkey. Proc Natl Acad Sci U S A (1971) 1.57
Structure of the mouse mammary tumor virus: polypeptides and glycoproteins. J Virol (1974) 1.56
Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol (2001) 1.52
Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas. Cancer Res (1986) 1.52
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res (2000) 1.52
Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther (1999) 1.52
Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res (2001) 1.51
Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med (1992) 1.49
A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer (1982) 1.47
Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members. J Nucl Med (2001) 1.47
Regression of duodenal gastric metaplasia in Helicobacter pylori positive patients with duodenal ulcer disease. Dig Liver Dis (2002) 1.46
In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med (1990) 1.41
Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res (1991) 1.41
Isolation of the mouse mammary tumor virus sequences not transmitted as germinal provirus in the C3H and RIII mouse strains. J Virol (1977) 1.39
Expression of laminin receptor in normal and carcinomatous human tissues as defined by a monoclonal antibody. Cancer Res (1985) 1.37
Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res (2001) 1.35
Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother (2000) 1.35
Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res (1985) 1.35
Expression of ras oncogene p21 in prostate cancer. N Engl J Med (1986) 1.35
Structure of the mouse mammary tumor virus: characterization of bald particles. J Virol (1974) 1.35
Virus-related RNA in human and mouse mammary tumors. J Natl Cancer Inst (1972) 1.34
Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res (1997) 1.34
Monoclonal antibodies to the human laminin receptor recognize structurally distinct sites. Exp Cell Res (1985) 1.32
Relationship in nucleic acid sequences between mouse mammary tumor virus variants. Proc Natl Acad Sci U S A (1975) 1.32
Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. Proc Natl Acad Sci U S A (1984) 1.32
A biochemical approach to the study of the transmission of mouse mammary tumor viruses in mouse strains RIII and C3H. Int J Cancer (1976) 1.30
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res (2000) 1.30
A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res (1999) 1.28
Detection of high-molecular-weight RNA in particles from human milk. Science (1972) 1.27
ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma. J Exp Med (1985) 1.26
Antigenic comparison of feline coronavirus isolates: evidence for markedly different peplomer glycoproteins. J Virol (1987) 1.25
Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res (1988) 1.25
Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine (1997) 1.24
Expression in COS cells of a mouse-human chimaeric B72.3 antibody. Protein Eng (1987) 1.23
Biochemical properties of the bromodeoxyuridine-induced guinea pig virus. J Virol (1975) 1.22
Serological and biochemical characterization of the mouse mammary tumor virus with localization of p10. Virology (1978) 1.22
Quantitation of RNA tumor viruses and viruslike particles in human milk by hybridization to polyadenylic acid sequences. Science (1973) 1.21
Mason-Pfizer virus RNA genome: relationship to the RNA of morphologically similar isolates and other oncornaviruses. J Virol (1976) 1.20
Independent polypeptide chain initiation sites for the synthesis of different classes of proteins for an RNA tumor virus: mouse mammary tumor virus. Virology (1976) 1.20
A comparative study of the biologic and molecular basis of murine mammary carcinoma: a model for human breast cancer. J Natl Cancer Inst (1973) 1.19
Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res (1999) 1.17
Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res (1989) 1.16
Type-specific antigenic determinants on the major external glycoprotein of high- and low-oncogenic murine mammary tumor viruses. J Virol (1977) 1.16
A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother (1999) 1.16
Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol (2011) 1.15
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res (1999) 1.15